Fresenius agrees two acquisitions to bolster Kabi drugs unit –

Fresenius headquarters in Bad Homburg near Frankfurt, Germany, February 27, 2018. REUTERS/Ralph Orlowski
FRANKFURT, March 31 (Reuters) – Fresenius's (FREG.DE) generic drugs unit Kabi has agreed to buy a majority stake in the mAbxience division of Spain's Insud Pharma to expand its business making cheaper versions of biotechnology drugs that have lost patent protection.
The German healthcare group said on Thursday it would acquire a 55% stake in mAbxience, a maker of affordable biosimilar versions of cancer drugs MabThera and Avastin, for 495 million euros ($553 million), plus milestone payments contingent on commercial and development targets.
Fresenius will also have an option to buy the remaining shares in mAbxience under certain terms.
In its statement, Fresenius said Kabi had also agreed to acquire Ivenix Inc, a maker of infusion therapies, for $240 million upfront, plus milestone payments.
Privately-held Ivenix, based in Massachusetts, developed an infusion system and software that received U.S. Food and Drug Administration (FDA) approval last year, which Kabi will combine with its offering of intravenous fluids and infusion devices. Fresenius has identified Kabi as a core growth business. It has not ruled out a sale of its kidney dialysis division FMC (FMEG.DE) and left the door open for initial public offerings for healthcare project development unit Vamed and its hospitals chain Helios.
($1 = 0.8955 euros)
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Add a Comment

Your email address will not be published.